Advances In Anatomic Pathology最新文献_第5页

The "Other" Uterine Mesenchymal Neoplasms: Recent Developments and Emerging Entities. 其他 "子宫间质肿瘤：最新进展与新兴实体。

IF 6.7 2区医学

Advances In Anatomic Pathology Pub Date : 2024-04-16 DOI: 10.1097/pap.0000000000000440

Jennifer A Bennett, Andre Pinto

引用次数: 0

Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy. 新辅助治疗后手术切除肺癌的病理学研究

IF 6.7 2区医学

Advances In Anatomic Pathology Pub Date : 2024-04-09 DOI: 10.1097/pap.0000000000000441

Sabina Berezowska, Mark Keyter, Hasna Bouchaab, Annikka Weissferdt

{"title":"Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy.","authors":"Sabina Berezowska, Mark Keyter, Hasna Bouchaab, Annikka Weissferdt","doi":"10.1097/pap.0000000000000441","DOIUrl":"https://doi.org/10.1097/pap.0000000000000441","url":null,"abstract":"In around 30% of patients, non-small cell lung cancer is diagnosed at an advanced but resectable stage. Adding systemic therapy has shown clear benefit over surgery alone in locally advanced disease, and currently, chemo-immunotherapy in the adjuvant or neoadjuvant setting is the new standard for patients without targetable mutations. One major advantage of the neoadjuvant approach is the possibility of an immediate evaluation of the treatment effect, highlighting the role of pathology as an important contributor at the forefront of clinical decision-making and research. This review provides a summary and an update on current guidelines for histological evaluation of treatment effect after neoadjuvant therapy, also known as regression grading, and discusses newer data focusing on areas of evolving questions and controversies, such as the gross examination of the tumor and tumor bed, weighted versus unweighted evaluation approaches, discussion of histologic tumor type-specific cut-offs for major pathologic response, assessment of lymph nodes and regression grading after immunotherapy and targeted therapy. As no data or recommendations exist on regression grading of multiple tumor nodules, a practical approach is recommended. Lastly, we will touch on additional tissue biomarkers and summarize recent advances in the ardently discussed field of using circulating tumor DNA for the evaluation of treatment response.","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140593516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding Factors that Influence Prognosis and Response to Therapy in Clear Cell Renal Cell Carcinoma. 了解影响透明细胞肾细胞癌预后和治疗反应的因素。

IF 6.7 2区医学

Advances In Anatomic Pathology Pub Date : 2024-03-01 Epub Date: 2024-01-05 DOI: 10.1097/PAP.0000000000000428

Liwei Jia, Lindsay G Cowell, Payal Kapur

引用次数: 0

Contemporary Updates on Sex Cord-stromal Tumors of the Testis. 睾丸性索间质肿瘤的当代最新进展。

IF 6.7 2区医学

Advances In Anatomic Pathology Pub Date : 2024-03-01 Epub Date: 2023-12-06 DOI: 10.1097/PAP.0000000000000423

Andrés M Acosta, Muhammad T Idrees, Daniel M Berney, Maurizio Colecchia

引用次数: 0

Update on Selected High-grade Renal Cell Carcinomas of the Kidney: FH-deficient, ALK-rearranged, and Medullary Carcinomas. 部分肾高级别肾细胞癌的最新进展：FH缺陷型、ALK重排型和髓样癌。

IF 5.1 2区医学

Advances In Anatomic Pathology Pub Date : 2024-03-01 Epub Date: 2023-12-25 DOI: 10.1097/PAP.0000000000000426

Ying-Bei Chen

{"title":"Update on Selected High-grade Renal Cell Carcinomas of the Kidney: FH-deficient, ALK-rearranged, and Medullary Carcinomas.","authors":"Ying-Bei Chen","doi":"10.1097/PAP.0000000000000426","DOIUrl":"10.1097/PAP.0000000000000426","url":null,"abstract":"High-grade renal cell carcinoma (RCC), often diagnosed at advanced stages, significantly contributes to renal cancer-related mortality. This review explores the progress in understanding specific subtypes of high-grade RCC, namely fumarate hydratase (FH)-deficient RCC, anaplastic lymphoma kinase (ALK)-rearranged RCC, and SMARCB1-deficient renal medullary carcinoma, all of which are now recognized as molecularly defined entities in the WHO classification system (2022). While these entities each exhibit a morphologic spectrum that overlaps with other high-grade RCC, ancillary tools developed based on their distinctive molecular alterations can help establish a specific diagnosis, underscoring the importance of integrating molecular findings into diagnostic paradigms. It is important to exclude these specific tumor types in cases with similar morphologic spectrum before rendering a diagnosis of high-grade papillary RCC, collecting duct carcinoma, or RCC, NOS. Several gray areas exist within the spectrum of high-grade uncommon types of RCC, necessitating continued research to enhance diagnostic precision and therapeutic options.","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":null,"pages":null},"PeriodicalIF":5.1,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139032093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glandular Lesions of the Urinary Bladder: Diagnostic and Molecular Updates. 膀胱腺体病变：诊断和分子更新。

IF 6.7 2区医学

Advances In Anatomic Pathology Pub Date : 2024-03-01 Epub Date: 2024-02-07 DOI: 10.1097/PAP.0000000000000432

Henning Reis, Gladell P Paner

引用次数: 0

IF 6.7 2区医学

Advances In Anatomic Pathology Pub Date : 2024-03-01 Epub Date: 2024-01-15 DOI: 10.1097/PAP.0000000000000431

Anuradha Gopalan

{"title":"Treatment-related Neuroendocrine Prostate Carcinoma-Diagnostic and Molecular Correlates.","authors":"Anuradha Gopalan","doi":"10.1097/PAP.0000000000000431","DOIUrl":"10.1097/PAP.0000000000000431","url":null,"abstract":"Treatment-related neuroendocrine prostate cancer is a distinctive category of prostate cancer that arises after intensive suppression of the androgen receptor by next-generation therapeutic inhibition of androgen receptor signaling. The biological processes that set in motion the series of events resulting in transformation of adenocarcinoma to neuroendocrine carcinoma include genomic (loss of tumor suppressors TP53 and RB1, amplification of oncogenes N-MYC and Aurora Kinase A, dysregulation of transcription factors SOX2, achaete-scute-homolog 1, and others) as well as epigenomic (DNA methylation, EZH2 overexpression, and others). Pathologic diagnosis is key to effective therapy for this disease, and this is aided by localizing metastatic lesions for biopsy using radioligand imaging in the appropriate clinical context. As our understanding of biology evolves, there has been increased morphologic recognition and characterization of tumor phenotypes that are present in this advanced post-treatment setting. New and promising biomarkers (delta-like ligand 3 and others) have been discovered, which opens up novel therapeutic avenues including immunotherapy and antibody-drug conjugates for this lethal disease with currently limited treatment options.","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139465869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary Issues in Urothelial Carcinoma of Upper Urinary Tract. 上尿路尿路上皮癌的当代问题。

IF 6.7 2区医学

Advances In Anatomic Pathology Pub Date : 2024-03-01 Epub Date: 2023-11-27 DOI: 10.1097/PAP.0000000000000421

Jianping Zhao, Charles C Guo, Priya Rao

{"title":"Contemporary Issues in Urothelial Carcinoma of Upper Urinary Tract.","authors":"Jianping Zhao, Charles C Guo, Priya Rao","doi":"10.1097/PAP.0000000000000421","DOIUrl":"10.1097/PAP.0000000000000421","url":null,"abstract":"Upper urinary tract urothelial carcinoma (UTUC) is an uncommon malignancy involving the renal pelvis and ureter. Careful pathologic analysis plays a critical role in the diagnosis and clinical management of UTUC. In combination with clinical and radiologic evaluation, pathologic features can be used to stratify patients into low-risk and high-risk groups. This risk stratification can help clinicians select the optimal treatment for patients with UTUC, such as kidney-sparing (conservative) treatment, radical nephroureterectomy or ureterectomy, and perioperative systemic therapy. However, due to the technical difficulty of obtaining sufficient tissue from the upper urinary tract, it is often challenging for pathologists to accurately grade the tumor and assess tumor invasion in small biopsy specimens. Although the majority of UTUCs are pure urothelial carcinoma, a considerable subset of UTUCs show histologic subtypes or divergent differentiation. Recent studies have identified genetically distinct molecular subtypes of UTUC by examining DNA, RNA, and protein expression profiles. The prognosis of pT3 UTUC, particularly renal pelvic UC, remains controversial, and several studies have proposed subclassification of pT3 UTUC. Lynch syndrome is a significant risk factor for UTUC, and screening tests may be considered in young patients and those with familial histories of the disease. Despite significant progress in recent years, several issues remain to be addressed in the pathologic diagnosis, molecular classification, and treatment of UTUC.","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10922730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138440151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up. 与TSC/MTOR基因改变相关的肾细胞癌：其扩展谱的更新和临床病理研究方法。

IF 6.7 2区医学

Advances In Anatomic Pathology Pub Date : 2024-03-01 Epub Date: 2023-10-30 DOI: 10.1097/PAP.0000000000000419

Rajal B Shah, Rohit Mehra

{"title":"Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up.","authors":"Rajal B Shah, Rohit Mehra","doi":"10.1097/PAP.0000000000000419","DOIUrl":"10.1097/PAP.0000000000000419","url":null,"abstract":"Renal cell carcinoma (RCC) with tuberous sclerosis complex (TSC)/mammalian target of rapamycin (MTOR) pathway-related genomic alterations have been classically described in hereditary TSC syndrome setting involving germline mutations, whereby cells with a bi-allelic inactivation of genes originate tumors in a classic tumor-suppressor \"two-hit\" Knudson paradigm. Initial studies of TSC-associated RCC categorized tumors into 3 broad heterogeneous morphologic groups: RCC with smooth muscle stroma, chromophobe-like, and eosinophilic-macrocytic. Recently, a similar morphologic spectrum has been increasingly recognized in novel and emerging entities characterized by somatic mutations in the TSC1/2 and MTOR in patients who do not suffer from the TSC. Correct recognition of RCC with TSC / MTOR mutations is critical for accurate prognostication because such tumors with aggressive behavior have the potential to be tailored to mTOR inhibitors. Whether TSC/MTOR mutated renal epithelial neoplasms represent a distinct molecular class has been confounded by the fact that TSC1/2 , and the gene encoding the downstream protein MTOR, are mutated secondarily in ∼5% of the more common subtypes of RCC, including the commonest subtype of clear cell RCC. This review summarizes the expanding morphologic spectrum of renal tumors with TSC/mTOR pathway alterations, specifically for sporadically occurring tumors where these genomic alterations likely are primary pathologic events. Finally, a practical surgical pathology approach to handling these tumors, and a conceptual framework of renal epithelial tumors with TSC/MTOR mutations as a \"family of tumors\", is presented.","PeriodicalId":7305,"journal":{"name":"Advances In Anatomic Pathology","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71410123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic Prostate Cancer. 晚期和转移性前列腺癌的DNA损伤反应和错配修复基因缺陷。

IF 6.7 2区医学

Advances In Anatomic Pathology Pub Date : 2024-03-01 Epub Date: 2023-11-27 DOI: 10.1097/PAP.0000000000000422

Dilara Akhoundova, Paola Francica, Sven Rottenberg, Mark A Rubin

引用次数: 0